EE+ POEM Archive
PSK9 inhibitor alirocumab reduces nonfatal MI in patients after acute coronary syndrome, but at high cost (ODYSSEY OUTCOMES)
PSK9 inhibitor alirocumab reduces nonfatal MI in patients after acute coronary syndrome, but at high cost (ODYSSEY OUTCOMES) is a topic covered in the EE+ POEM Archive.
To view the entire topic, please log in or purchase a subscription.
Evidence Central is an integrated web and mobile solution that helps clinicians quickly answer etiology, diagnosis, treatment, and prognosis questions using the latest evidence-based research. Explore these free sample topics:
There's more to see -- the rest of this topic is available only to subscribers.
Citation
Barry, Henry, et al., editors. "PSK9 Inhibitor Alirocumab Reduces Nonfatal MI in Patients After Acute Coronary Syndrome, but at High Cost (ODYSSEY OUTCOMES)." EE+ POEM Archive, John Wiley & Sons, 2019. Evidence Central, evidence.unboundmedicine.com/evidence/view/infoPOEMs/1314667/all/PSK9_inhibitor_alirocumab_reduces_nonfatal_MI_in_patients_after_acute_coronary_syndrome__but_at_high_cost__ODYSSEY_OUTCOMES_.
PSK9 inhibitor alirocumab reduces nonfatal MI in patients after acute coronary syndrome, but at high cost (ODYSSEY OUTCOMES). In: Barry HH, Ebell MHM, Shaughnessy AFA, et al, eds. EE+ POEM Archive. John Wiley & Sons; 2019. https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/1314667/all/PSK9_inhibitor_alirocumab_reduces_nonfatal_MI_in_patients_after_acute_coronary_syndrome__but_at_high_cost__ODYSSEY_OUTCOMES_. Accessed March 22, 2023.
PSK9 inhibitor alirocumab reduces nonfatal MI in patients after acute coronary syndrome, but at high cost (ODYSSEY OUTCOMES). (2019). In Barry, H., Ebell, M. H., Shaughnessy, A. F., & Slawson, D. C. (Eds.), EE+ POEM Archive. John Wiley & Sons. https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/1314667/all/PSK9_inhibitor_alirocumab_reduces_nonfatal_MI_in_patients_after_acute_coronary_syndrome__but_at_high_cost__ODYSSEY_OUTCOMES_
PSK9 Inhibitor Alirocumab Reduces Nonfatal MI in Patients After Acute Coronary Syndrome, but at High Cost (ODYSSEY OUTCOMES) [Internet]. In: Barry HH, Ebell MHM, Shaughnessy AFA, Slawson DCD, editors. EE+ POEM Archive. John Wiley & Sons; 2019. [cited 2023 March 22]. Available from: https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/1314667/all/PSK9_inhibitor_alirocumab_reduces_nonfatal_MI_in_patients_after_acute_coronary_syndrome__but_at_high_cost__ODYSSEY_OUTCOMES_.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - PSK9 inhibitor alirocumab reduces nonfatal MI in patients after acute coronary syndrome, but at high cost (ODYSSEY OUTCOMES)
ID - 1314667
ED - Barry,Henry,
ED - Ebell,Mark H,
ED - Shaughnessy,Allen F,
ED - Slawson,David C,
BT - EE+ POEM Archive
UR - https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/1314667/all/PSK9_inhibitor_alirocumab_reduces_nonfatal_MI_in_patients_after_acute_coronary_syndrome__but_at_high_cost__ODYSSEY_OUTCOMES_
PB - John Wiley & Sons
DB - Evidence Central
DP - Unbound Medicine
ER -
